MedWatch

Ascendis launches growth hormone Skytrofa in the US

In August, the company brought home an FDA approval for the once-weekly growth hormone Skytrofa. The biotech company Ascendis Pharma is now ready to send the drug to market.

Photo: Kevin Grønnemann

A month and a half since securing the approval from the US Food and Drug Administration (FDA), Ascendis Pharma is ready to market the drug Skytrofa, which addresses the need of children suffering from growth hormone deficiency, informs the company in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs